Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes (Q45052086)

8 December 2017

Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes (English)

1 reference

8 December 2017

3

1 reference

8 December 2017

Rafael Prado-Gotor

7

0 references

Paolo Lusso

12

object named as

Paolo Lusso

1 reference

8 December 2017

Loïc Martin

1

1 reference

8 December 2017

François Stricher

2

1 reference

8 December 2017

Francesca Sironi

4

1 reference

8 December 2017

Martine Pugnière

5

1 reference

8 December 2017

Philippe Barthe

6

1 reference

8 December 2017

Isabelle Freulon

8

1 reference

8 December 2017

Xavier Magne

9

1 reference

8 December 2017

Christian Roumestand

10

1 reference

8 December 2017

André Ménez

11

1 reference

8 December 2017

Francisco Veas

13

1 reference

8 December 2017

Claudio Vita

14

1 reference

8 December 2017

16 December 2002

1 reference

8 December 2017

1 reference

8 December 2017

21

1 reference

8 December 2017

1

1 reference

8 December 2017

71-76

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt768

8 December 2017

0 references

cites work

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

21 January 2018

1 reference

The antigenic structure of the HIV gp120 envelope glycoprotein

21 January 2018

1 reference

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

21 January 2018

1 reference

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

21 January 2018

1 reference

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

21 January 2018

1 reference

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes

21 January 2018

1 reference

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

21 January 2018

1 reference

Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates

21 January 2018

1 reference

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

21 January 2018

1 reference

HIV entry and its inhibition

21 January 2018

1 reference

Mechanisms of viral membrane fusion and its inhibition

21 January 2018

1 reference

Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies

21 January 2018

1 reference

Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic

21 January 2018

1 reference

Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein

21 January 2018

1 reference

Scorpion toxins as natural scaffolds for protein engineering

21 January 2018

1 reference

Energetics of the HIV gp120-CD4 binding reaction

21 January 2018

1 reference

Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding

21 January 2018

1 reference

In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

21 January 2018

1 reference

Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.

21 January 2018

1 reference

Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus

21 January 2018

1 reference

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates

21 January 2018

1 reference

Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team

21 January 2018

1 reference

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

Reduced antiretroviral drug susceptibility among patients with primary HIV infection

21 January 2018

1 reference

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

21 January 2018

1 reference

Torsion angle dynamics for NMR structure calculation with the new program DYANA

21 January 2018

1 reference

MOLMOL: a program for display and analysis of macromolecular structures

21 January 2018

1 reference

Structural and functional analysis of the RANTES-glycosaminoglycans interactions

21 January 2018

1 reference

Molecular cloning and functional expression of a new human CC-chemokine receptor gene

21 January 2018

1 reference

HIV-1 Reverse Transcription A Termination Step at the Center of the Genome

21 January 2018

1 reference

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization

21 January 2018

1 reference

7 January 2021

Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.

1 reference

7 January 2021

Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules

1 reference

7 January 2021

Expression and Characterization of CD4-IgG2, a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates

1 reference

7 January 2021

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

7 January 2021

Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

1 reference

7 January 2021

Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4

1 reference

7 January 2021

Dissociation of the CD4 and CXCR4 binding properties of human immunodeficiency virus type 1 gp120 by deletion of the first putative alpha-helical conserved structure.

1 reference

7 January 2021

Identifiers

DOI

10.1038/NBT768

1 reference

Dimensions Publication ID

8 December 2017

0 references

1 reference